Continuous Renal Replacement Therapy in patients with HIV/AIDS

Hebing Guo

Capital Medical University Affiliated Beijing Ditan Hospital

Jingyuan Liu

Capital Medical University Affiliated Beijing Ditan Hospital

Lin Pu

Capital Medical University Affiliated Beijing Ditan Hospital

Jingjing Hao

Capital Medical University Affiliated Beijing Ditan Hospital

Ningning Yin

Capital Medical University Affiliated Beijing Ditan Hospital

Yufeng Liu

Capital Medical University Affiliated Beijing Ditan Hospital

Haofeng Xiong

Capital Medical University Affiliated Beijing Ditan Hospital

Ang Li (✉ dtyyicu@163.com)

Capital Medical University Affiliated Beijing Ditan Hospital

Research article

Keywords: HIV/AIDS, CRRT, Mortality, Risk Factors

Posted Date: February 14th, 2020

DOI: <https://doi.org/10.21203/rs.2.20631/v2>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background :AKI is a common complication among human immunodeficiency virus (HIV)–infecting patients and resulting in increased morbidity and mortality. CRRT is a useful method and instrument in critically ill patients with fluid overload and metabolic disarray, especially in those who are unable to tolerate the intermittent hemodialysis. However, the epidemiology, influence factors of CRRT and mortality in patients with HIV/AIDS are still unclear in China. This study aims to study the HIV-infected patients admitted in ICU and explore the influence factors correlated with CRRT and prognosis.**Methods:** We performed a retrospective case-control study, in ICU of Beijing Ditan Hospital Capital Medical University, which is a top three hospital majoring in infectious diseases. From June 1,2005 to May 31,2017, 225 cases were enrolled in this research eventually.**Results:** 122(54.2%) patients were diagnosed with AKI during their stay in ICU, the number and percentage of AKI stage 1/2/3 were respectively 38(31.1%)/23(18.9%)/61(50%). 26.2% of AKI patients received CRRT during the stay of ICU. 56.25% CRRT patients died in ICU. The 28-day mortality was 62.5%, and the 90-day mortality was 75%. By multivariate logistics analysis, it showed that the use of vasoactive agents (OR=174.31,95% CI 1.743-65.271, $p=0.018$), diagnosis of PCP(OR=27.136,95% CI 1.855-397.066, $p=0.016$) and longer duration of CRRT (OR=1.034,95% CI 1.004-1.065, $p=0.028$) were independent risk factors for predicting patients' death of CRRT in ICU. The Cox Analysis for the cumulative survival of AKI 3 patients between the CRRT and non-CRRT groups shows no significant differences ($p =0.309$).**Conclusions:** The incidence of AKI was 54.2% in HIV-infected patients admitted to the ICU, and about 26.2% AKI patients received CRRT during the stay of ICU.56.25%CRRT patients died in ICU. The 28-day mortality was 62.5%, and the 90-day mortality was 75%. The use of vasoactive agents, diagnosis of PCP were independent risk factors for predicting patients' death of CRRT in ICU. The cumulative survival of AKI 3 patients between CRRT and non-CRRT groups shows no significant differences.

Introduction

Acute kidney injury (AKI) is a common disease in critical patients and affects more than 13 million people all around the world annually [1]. Patients who are infected by human immunodeficiency virus (HIV) are more vulnerable to suffer from AKI and showing a higher mortality and morbidity [2, 3]. 66% HIV-infected patients are diagnosed with AKI during their stay in the Intensive Care Unit (ICU)[4]. Continuous renal replacement therapy (CRRT) has been an important maintenance intervention in patients with severe AKI for more than one decade [5, 6]. However, few studies have clarified CRRT in patients with HIV/AIDS. Epidemiology and influence factors of CRRT in patients with HIV/AIDS are still unclear in China. This study aims to make these determinations among HIV-infected individuals in an observational retrospective clinical study.

Methods

Study design and population

The study is a retrospective research in ICU of the Beijing Ditan Hospital Capital Medical University which is one of the top three hospital for infectious diseases. About five hundred patients were admitted in this general ICU and there were 20-bed ward for both medical and surgical patients each year. We reviewed the Hospital Information management System (HIS) from June 1, 2005 to May 31, 2017 in Beijing Ditan Hospital Capital Medical University for this study. All of the databases were recorded and analyzed by infectiology specialists from our team. Patients who were clearly diagnosed with HIV and older than 18 years old were included in this study. Patients who underwent RRT before admission, stayed in ICU less than 48 hours and were admitted in ICU more than once within 6 months, were excluded from this research. This study only recorded the first admission for patients who were admitted at ICU more than once within 6 months.

There were 284 cases admitted at ICU of Beijing Ditan Hospital Capital Medical University from June 1, 2005 to May 31, 2017. 47 cases were excluded because of the length of stay at ICU less than 48 hours. 4 cases were excluded by accepting renal replacement therapy before admission. Meanwhile 8 patients were recorded the first admission because of admitting at ICU twice within 6 months. A total of 225 cases were considered for this study.

No trial of any specific therapeutic or prophylactic intervention was carried out and only observational data were used for our analysis. This study was approved by the Ethics Committee of Beijing Ditan Hospital, Capital Medical University, No. 2018-005-01.

Definitions

AKI diagnosis

We used the Kidney Disease Improving Global Outcomes (KDIGO) criteria for the diagnosis of AKI. As defined by the KDIGO, AKI would be diagnosed if there is a 50% rise in serum creatinine from baseline at any point during the patient's prior 7-day ICU admission; a rise in serum creatinine of $>26.5\text{mmol/L}$ within a 48-h period; a fall in urine output of $<0.5\text{mL/kg/h}$ for more than 6 h; an absolute serum creatinine of $>353.6\text{mmol/L}$; or an RRT is initiated [7].

HIV diagnosis

As defined by the US Centers for Disease Control and Prevention (CDC) in a revised surveillance case definition for HIV infection in 2014, HIV infection is diagnosed when a positive result from HIV antibody or combination of an antigen/antibody test is obtained, and another positive result is obtained from a supplemental different HIV test, performed in parallel or subsequently to the initial test [8]. Alternatively, HIV infection is diagnosed if a positive result or report of a detectable quantity from any of the following HIV virologic tests has been obtained:

- Qualitative HIV NAT (DNA or RNA)– Quantitative HIV NAT (viral load assay)
- HIV-1 p24 antigen test

- HIV isolation (viral culture) or
- HIV nucleotide sequence (genotype) [9]

Data collection

The following demographic, clinical, laboratory data, complication and multiple organs support therapy were collected from the patient medical manuals and an electronic hospital database by four investigators (H. Guo, L. Pu, J. Hao, and N. Yin): age, sex, body mass index, lymphocyte count, hemoglobin, albumin, t-bil, serum calcium, lactate, sodium bicarbonate, serum phosphate, Glomerular Filtration Rate (GRF), Mean Platelet Volume (MPV), Alanine Transaminase (ALT), glutamic oxalacetic transaminase (AST), Lactate Dehydrogenase (LDH), CD4 count at ICU admission, lowest CD4 count in ICU, Highly Active Anti-Retroviral Therapy (HAART), Pneumocystis Carinii Pneumonia (PCP), septic shock, respiratory failure, the use of vasoactive agents, duration of mechanical ventilation, duration of CRRT.

The severity of illness was evaluated by the Sequential Organ Failure Assessment (SOFA) and the Acute Physiology and Chronic Health Evaluation (APACHE)II score, which calculation was based on the worst variables recorded within the first 24 h of ICU admission.

All patients received CRRT through continuous venovenous hemodiafiltration (CVVHDF) (therapeutic dose of 30 ml/kg) and the related data were not recorded in this study.

Length of ICU stay and hospital were recorded in the Electronic Hospital Database.

Outcome measures

Outcome was recorded by the HIS of Beijing Ditan Hospital Capital Medical University. Follow-up visit was conducted by infectious diseases specialists by telephone in this study.

Statistical analysis

Categorical variables were compared using a chi-squared test for trends. Risk factors were assessed by univariate analyses, and variables that were statistically significant ($p < 0.05$) in the univariate analyses were later included in a multivariate analysis. Univariate and multivariate analyses were performed using a logistic regression. The life table method was used to determine survival curves, and a Cox proportional hazards model was used to evaluate the statistical differences between the survival and non-survival curves. Data are presented as mean $\pm$ standard deviation, median (interquartile range), percentage of number of cases, odds ratios (ORs) with 95% confidence intervals. A two-tailed $p < 0.05$ was considered significant. Statistical analyses were performed using the SPSS version 22.0 software (SPSS, Inc., Chicago, IL).

Results

Patients characteristics

Among the 225 patients, 205 (91.1%) were male. The average age of the total numbers was 42 ± 13 years. 122(54.2%) patients were diagnosed with AKI during their stay at ICU. As shown in Figure 1, the number and percentage of AKI stage 1/2/3 were respectively 38 (31.1%)/23 (18.9%)/61 (50%). 32 patients (about 26.2% of total AKI) received continuous renal replacement therapy (CRRT) at ICU. 2 patients started the CRRT with a stage 2, the others (n=30) started at stage 3. 56.25% (n=18) of patients who received CRRT died at ICU.

Comparison between AKI patients with CRRT and without are shown in Table 1. Hemoglobin and CD4 counts at ICU admission had a statistically significant difference ($p=0.048$ and $p=0.043$, respectively). As per complications, the incidence of *Pneumocystis carinii* pneumonia (PCP) and respiratory failure showed a statistical significant difference ($p=0.006$ and $p=0.01$, respectively). In severity of illness, patients with CRRT were even worse both in SOFA and APACHE-II score ($p \leq 0.001$, and $p \leq 0.001$, respectively). Patients with CRRT stayed in the hospital for a shorter period than those without ($p=0.022$).

As shown in Figure 2, 9/13 patients (40.6%) who were admitted at ICU for respiratory failure, died at ICU. Secondly, 2/10 patients (31.25%) who received treatment at ICU mainly for AKI, died at ICU. Septic shock, intestinal perforation, cardiopulmonary arrest, central nervous system disease were the other factors for admission at ICU.

Table 3 and table 4 show the strength of association between death at ICU and its potential risk factors, respectively and were calculated by univariate and multivariate logistics analysis. The result showed that respiratory failure, septic shock, the use of vasoactive agents, duration of mechanical ventilation, diagnosis of PCP, SOFA score at ICU admission, were independent risk factors for CRRT by univariate logistics analysis, respectively.

Higher likelihood of diagnosis for respiratory failure (OR=7.333,95% CI 1.467-36.664, $p=0.015$), higher likelihood of diagnosis for septic shock (OR=12.5,95% CI 2.29-68.245, $p=0.004$), and higher likelihood to use vasoactive agents (OR=10.667,95% CI 1.743-65.271, $p=0.01$), longer mechanical ventilation duration (OR=1.011,95% CI 1.002-1.019, $p=0.011$), higher likelihood for diagnosis for PCP (OR=7.50,95% CI 1.288-43.687, $p=0.025$), higher SOFA score at ICU admission (OR=1.183,95% CI 1.012-1.383, $p=0.035$), longer duration of CRRT (OR=1.014,95% CI 1.001-1.028, $p=0.034$) contributed to a higher mortality at ICU.

The multivariate logistics analysis showed that diagnosis of septic shock, diagnosis of PCP and longer duration of CRRT were independent risk factors for predicting patients' death of CRRT at ICU. A higher likelihood of diagnosis for septic shock (OR=151.256,95% CI 2.842-8051.975, $p=0.013$), higher likelihood of diagnosis for PCP (OR=52.698,95% CI 1.092-2543.904, $p=0.045$), longer duration of CRRT (OR=1.045,95% CI 1.007-1.085, $p=0.02$) contributed to a higher risk of death at ICU.

As shown in Figure 1, most of AKI patients (n=30, 93.75% of AKI patients) received CRRT at stage 3. Among the 3 AKI patients, about a half received CRRT during their stay at ICU. Then we compared the two groups shown in table 2. Plasma-albumin and CD4 counts at ICU admission had a statistically significant difference ($p=0.046$ and $p=0.007$, respectively). In severity of illness, patients who received CRRT had a

higher APACHE-II scores ($p=0.019$). Even with CRRT, the main outcome, such as the mortality at ICU, and the renal recovery in the two groups did not show a significant difference ($p=0.373$ and $p=0.437$, respectively). Patients who received CRRT probably had a longer stay tendency at ICU ($p=0.529$), but a shorter hospital stay ($p=0.034$).

As shown by the cumulative survival curves of HIV-infected patients who were diagnosed with AKI 3 admitted to the intensive care unit (Figure 3), the group of CRRT and non-CRRT had no significant difference ($p=0.309$). As determined by the Cox Analysis of the cumulative survival of 3 AKI patients between the CRRT and non-CRRT groups (table 5), the possibility of using vasoactive agents and duration of Mechanical ventilation shows a significant difference on 3 AKI patients' survival ($p=0.014$, OR 2.501, 95% CI 1.205-5.192 and $p=0.006$, OR 0.998, 95% CI 0.997-0.999, respectively).

Discussion

Lin Pu has concluded that AKI occurred more than 50% on HIV-infected patients admitted to the ICU [10]. Consistent with previous reports: the incidence of AKI for the patients admitted at ICU is 67% [10]. CRRT has practically and efficiently used in patients with AKI as a basic equipment [11, 12]. But the occurrence rate and influencing factors to predict patients' death of CRRT in ICU among the Chinese population is still unclear.

26.2% patients with AKI received CRRT during their stay at ICU in this study, at a significantly higher proportion than 5-6% patients without HIV [2]. The result indicated that HIV-infected patients were more prone to develop severe AKI. Patients with HIV lost kidney function faster than the overall population [13, 14]. Exposure to nephrotoxic drugs such as tenofovir and HIV replicating in other cells besides CD4 cells may aggravate deterioration of the renal function [15-17]. Rasch et al. found that the possibility of HIV patients receiving RRT were more than 4-fold compared with the overall population without RRT. Age, hypertension and AIDS were associated with an increased risk of RRT [15].

There is no difference with a previous study: the mortality ranging from 37-88% for the patients admitted at ICU who needed the RRT [18]. The study indicated that 56.25% of CRRT patients died at ICU. Mortality was higher in patients with HIV/AIDS, most likely due to the serious immunosuppression and opportunistic diseases [19]. Compared with survivals with CRRT, 15 non-survived patients suffered from septic shock during their stay at ICU.

Death of patients at ICU was more frequent if they were diagnosed with septic shock, PCP, or had a longer duration of CRRT. Ling ping et al. reported that sepsis-related AKI and using vasopressors were independent risk factors to increase patients' mortality [20]. Dopamine and norepinephrine are two types of common vasopressors widely used in curing different types of shocks. Patients with septic shock are usually affected by hypotension and coagulopathy [21]. Multiple organ syndrome occurred as a result of ischemia reperfusion injury. Use of vasoactive agents using might increase the risk of ICU death by the poor cardiovascular response to the catecholamine. Chou et al. reported that critically ill patients being

treated with a high dose of vasopressor also had a higher ICU mortality, with CRRT not improving patients' prognosis [22].

Patients with HIV infection are more vulnerable to be affected by opportunistic infections. PCP has been a common manifestation during HIV infection in developed countries. It played an important role throughout the course of the disease and often as the initial manifestation of acquired immunodeficiency syndrome (AIDS) [23]. Meanwhile it resulted in lung injury and gas exchange by inducing a pulmonary inflammatory response. Tumor necrosis factor- α and other immunomodulatory molecules were released as a response to the infection [24, 25]. Prasad et al. found that patients with a higher FiO₂ requirements while ventilated and a higher vasoactive agent administration were inclined to have an early (within 24h) mortality [26]. PCP prophylaxis has been widely used in developed countries [23], but still not commonly used in developing countries. No patients received PCP prophylaxis in this study. On the other hand, 25-33% patients were not diagnosed of PCP before they were clearly diagnosed of HIV [27]. Early diagnosis of HIV-infection and PCP prophylaxis perhaps contributed to a decreased mortality of CRRT.

This study suggests that a longer duration of CRRT can contribute to patients' death at ICU. Longer duration of CRRT can increase the likelihood of a catheter related bloodstream infection (CRSBI) and more vulnerability of CRRT related complications. Scott found that there was no difference of pediatric survival rate between long and short duration of CRRT [28]. The longer duration of CRRT, the higher risk of complications the patients might have. The patients enrolled in this study were all immunodeficient, therefore any opportunistic infection can be fatal for them.

The 28-day mortality of patients with CRRT was 62.5% in this study, matching with the 62% found in sepsis-induced acute kidney injury patients undergoing CRRT in previous reports [29].

As shown in figure 2, 13 patients with a respiratory failure represent the highest proportion of the ICU admission, 10 (76.9%) patients died at ICU. 10 patients of AKI represent the second group of ICU admission, only 2 (20%) died at ICU. 3 patients accepted the treatment at ICU because of septic shock, 3 of total (75%) did not survive at ICU. The figure indicated that patients who were initially diagnosed with AKI had probably a better prognosis. On the contrary, the patients who were initially admitted at ICU for respiratory failure or septic shock, usually had a poor outcome compared to patients diagnosed with AKI and needed the help of CRRT.

With the extensively use of highly active antiretroviral therapy (HAART), the survival of HIV-infected patients have been significantly improved [30]. The use of antiretroviral drugs is another determinant factor to compromise the renal function and increase the risk for CRRT [31]. Previous studies indicated that both HIV infection and HAART were directly nephrotoxic [32-35]. We also confirmed that only 30 (24.6%) patients with AKI received the HAART during their stay at ICU, there was no significant difference between the CRRT group and the non-CRRT group. The reason why most patients never received the HAART was that 71.1% patients were diagnosed with HIV infection within 3 months, so the treatment was not started yet [36].

The count of CD4+ cells reflects the immune status of HIV-infected patients. A previous study has proven that CD4 count <200 cells/ml was an independent predictor of experiencing AKI [37]. Low CD4 count and AIDS are risk factors for HIV-infected people suffering from AKI [38]. Lower CD4 count made HIV patients more vulnerable to suffer from opportunistic infections and increased the risk of kidney injury[36]. The average CD4 count of AKI patients was 23 (8-78) cells/ml, and there was a statistically significant difference ($p=0.043$) between the CRRT group 37 (13-122) cells/ml and the non-CRRT group 15(7-69) cells/ml. But there was no significant difference ($p=0.464$) between the CRRT survival group 97 (25-156) cells/ml and the CRRT non-survival group 40 (15-110) cells/ml. CD4 count <200 cells/ml can lead to immune depression, however, there was no significant difference ($p=0.245$ and $p=0.863$) between the CRRT group and the non-CRRT group for sepsis and septic shock. The reason why there was no significant difference between the two groups on CD4 count is probably because the patients admitted at ICU were both suffering for severe immunosuppression and easier to be infected by different pathogens. Franceschini et al. concluded that with the decreasing of patients' CD4 count, the possibility of morbidity and mortality extensively increased [37].

By using the Cox Analysis for the cumulative survival of AKI 3 patients between the CRRT and non-CRRT groups in figure 3, we conclude that CRRT did not improve patients' long-term survival ($p=0.309$). Most likely, CRRT had an determinant effect in maintaining the stability of the internal environment and decreasing pre load of heart. While CRRT was a maintenance intervention, other critical conditions except renal injury might affect the outcome. But as the cumulative survival curves illustrated in figure 3, APACHE-II score at ICU admission of CRRT and non-CRRT group were separated 28(21-37) and 19(18-30), $p=0.019$. Data in the figure 3 indicated that patients in the CRRT group were more critical. The cumulative survival rate of the CRRT group was lower than the one in the non-CRRT group. The result indicated that AKI 3 might be not the proper stage to start an active intervention. Patients might benefit from an earlier intervention at AKI 1 or AKI 2.

Limitations

The number of CRRT events is relatively small, which limits statistical power of analyses. This is a retrospective study. Thus, a large, prospective, randomized, controlled study is needed. Further investigations on different modes and therapeutic dose should be conducted.

Conclusion

There is a high incidence of AKI in HIV-infected patients admitted in our ICU. Patients with severe AKI were more prone to be admitted for CRRT and have a consequent poor prognosis.

Declarations

Ethical Approval and Consent to participate This study was approved by the Ethics Committee of Beijing Ditan Hospital, Capital Medical University, No.2018-005-01.

Consent for publication

Not applicable

Availability of supporting data

The data generated and analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

This work was supported, in part, by funding from the Sail Plan program of Beijing Municipal Administration of Hospitals (ZYLX201827)

Authors' contributions

AL and JYL designed the research study and provided research ideas. LP, JJH, NNY, YFL, HFX read the literature and collected medical records. HBG was a major contributor in writing the manuscript. All authors read and approved the final manuscript.

Acknowledgements

Not applicable.

Authors' information

Hebing Guo:

Beijing Ditan Hospital, Capital Medical University.

Postal address: ICU Beijing Ditan Hospital, No. 8 Jingshundong Street, Chaoyang District, Beijing 100015, China.

E-mail: 18618342346@163.com

Jingyuan Liu:

Department of Critical Care Medicine, Beijing Ditan Hospital, Capital Medical University.

Postal address: ICU Beijing Ditan Hospital, No. 8 Jingshundong Street, Chaoyang District, Beijing 100015, China.

E-mail: liujingyuan.bj@hotmail.com

Lin Pu:

Department of Critical Care Medicine, Beijing Ditan Hospital, Capital Medical University.

Postal address: ICU Beijing Ditan Hospital, No. 8 Jingshundong Street, Chaoyang District, Beijing 100015, China.

E-mail: pulin1103@ccmu.edu.cn

Jingjing Hao:

Department of Critical Care Medicine, Beijing Ditan Hospital, Capital Medical University.

Postal address: ICU Beijing Ditan Hospital, No. 8 Jingshundong Street, Chaoyang District, Beijing 100015, China.

E-mail: haojingjing2008@126.com

Ningning Yin:

Department of Critical Care Medicine, Beijing Ditan Hospital, Capital Medical University.

Postal address: ICU Beijing Ditan Hospital, No. 8 Jingshundong Street, Chaoyang District, Beijing 100015, China.

E-mail: yinningning2008@126.com

Yufeng Liu:

Department of Critical Care Medicine, Beijing Ditan Hospital, Capital Medical University.

Postal address: ICU Beijing Ditan Hospital, No. 8 Jingshundong Street, Chaoyang District, Beijing 100015, China.

E-mail: liuyufengqq123@163.com

Haofeng Xiong:

Department of Critical Care Medicine, Beijing Ditan Hospital, Capital Medical University.

Postal address: ICU Beijing Ditan Hospital, No. 8 Jingshundong Street, Chaoyang District, Beijing 100015, China.

E-mail: xionghaofengmd@qq.com

***Corresponding Authors:**

Prof. Ang Li, Department of Critical Care Medicine, Beijing Ditan Hospital, Capital Medical University.

Postal address: ICU Beijing Ditan Hospital, No. 8 Jingshundong Street, Chaoyang District, Beijing 100015, China.

E-mail: dtyyicu@163.com

References

1. Lameire NH, Bagga A, Cruz D, De MJ, Endre Z, Kellum JA, Liu KD, Mehta RL, Pannu N, Van BW: **Acute kidney injury: an increasing global concern.** *Lancet* 2013, **382**(9887):170-179.
2. Shigehiko U, Kellum JA, Rinaldo B, Doig GS, Hiroshi M, Stanislao M, Miet S, Ian T, Catherine B, Ettiene M: **Acute renal failure in critically ill patients: a multinational, multicenter study.** *Jama the Journal of the American Medical Association* 2005, **294**(7):813-818.
3. Cohen SD, Chawla LS, Kimmel PL: **Acute kidney injury in patients with human immunodeficiency virus infection.** *Current Opinion in Critical Care* 2008, **14**(6):647-653.
4. Randall D, Brima N, Walker D, Connolly J, Laing C, Copas A, Edwards S, Batson S, Miller R: **Acute kidney injury among HIV-infected patients admitted to the intensive care unit.** *International Journal of Std & Aids* 2014, **26**(13):915.
5. Allegretti AS, Steele DJR, Jo Ann DK, Ednan B, Niles JL, Ishir B: **Continuous renal replacement therapy outcomes in acute kidney injury and end-stage renal disease: a cohort study.** *Critical Care* 2013, **17**(3):R109.
6. Lins RL, Elseviers MM, Niepen PVD, Hoste E, Malbrain ML, Damas P, Devriendt J, Investigators F: **Intermittent versus continuous renal replacement therapy for acute kidney injury patients admitted to the intensive care unit: results of a randomized clinical trial.** *Nephrol Dial Transplant* 2009, **24**(2):512-518.
7. Arif K: **KDIGO clinical practice guidelines for acute kidney injury.** *Nephron Clinical Practice* 2012, **120**(4):179-184.
8. Branson BM, Mermin J: **Establishing the diagnosis of HIV infection: New tests and a new algorithm for the United States.** *Journal of Clinical Virology* 2011, **52**(52 Suppl 1):S3-S4.
9. Home C: **Revised surveillance case definition for HIV infection—United States, 2014.** *Mmwr Recomm Rep* 2014, **63**(RR-03):1-10.
10. Hoste EA, Clermont G, Kersten A, Venkataraman R, Angus DC, Bacquer DD, Kellum JA: **RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis.** *Critical Care*, 10,3(2006-05-12) 2006, **10**(3):R73.
11. Allegretti AS, Steele DJ, David-Kasdan JA, Bajwa E, Niles JL, Bhan I: **Continuous renal replacement therapy outcomes in acute kidney injury and end-stage renal disease: a cohort study.** *Critical Care* 2013, **17**(3):R109.

12. Cappi SB, Sakr Y, Vincent JL: **Daily evaluation of organ function during renal replacement therapy in intensive care unit patients with acute renal failure.** *Journal of Critical Care* 2006, **21**(2):179-183.
13. Rasch MG, Engsig FN, Feldt-Rasmussen B, Kirk O, Kronborg G, Pedersen C, Gerstoft J, Obel N: **Renal function and incidence of chronic kidney disease in HIV patients: a Danish cohort study.** *Scandinavian Journal of Infectious Diseases* 2012, **44**(9):689.
14. Choi AI, Shlipak MGHunt PW: **HIV-infected persons continue to lose kidney function despite successful antiretroviral therapy.** *Aids* 2009, **23**(16):2143-2149.
15. Rasch MG, Marie H, Bo FR, Gitte K, Larsen CS, Court P, Gitte P, Jan G, Niels O: **Increased risk of dialysis and end-stage renal disease among HIV patients in Denmark compared with the background population.** *Nephrology Dialysis Transplantation* 2014, **29**(6):1232-1238.
16. Bruggeman LA, Ross MD, Tanji N, ., Cara A, ., Dikman S, ., Gordon RE, Burns GC, D'Agati VD, Winston JA, Klotman ME: **Renal epithelium is a previously unrecognized site of HIV-1 infection.** *Journal of the American Society of Nephrology* 2000, **11**(11):2079-2087.
17. Sonia RN, Elena A, Pablo L, Vincent S: **Renal toxicity associated with tenofovir use.** *Expert Opinion on Drug Safety* 2010, **9**(4):545.
18. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Workgroup TA: **Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group.** *Critical Care* 2004.
19. Daher EDF, Silva GBD, Junior, Vieira APF, Souza JBD, Falc?O FDS, Costa CRD, Lima RSA: **Acute kidney injury in a tropical country: a cohort study of 253 patients in an infectious diseases intensive care unit.** *Revista Da Sociedade Brasileira De Medicina Tropical* 2014, **47**(1):86-89.
20. Wu L, Zhang P, Yang Y, Jiang H, He Y, Xu C, Yan H, Guo Q, Luo Q, Chen J: **Long-term renal and overall survival of critically ill patients with acute renal injury who received continuous renal replacement therapy.** *Renal Failure* 2017, **39**(1):736-744.
21. Shum HP, Chan KC, Kwan MC, Yeung WT, Cheung WS, Yan WW: **Timing for initiation of continuous renal replacement therapy in patients with septic shock and acute kidney injury.** *Critical Care* 2013, **17**(6):643-643.
22. Che-Yi C, Hung-Chieh Y, Wei C, Jiung-Hsiun L, Hsin-Hung L, Yao-Lung L, Ya-Fei Y, Shu-Ming W, Chiu-Ching H: **Norepinephrine and hospital mortality in critically ill patients undergoing continuous renal replacement therapy.** *Artificial Organs* 2015, **35**(2):E11-E17.
23. Siegel M, Masur H, Kovacs J: **Pneumocystis jirovecii Pneumonia in Human Immunodeficiency Virus Infection.** *Seminars in Respiratory & Critical Care Medicine* 2016, **37**(02):243-256.
24. Vassallo R, Standing J, Ah: **Isolated Pneumocystis carinii cell wall glucan provokes lower respiratory tract inflammatory responses.** *Journal of Immunology* 2000, **164**(7):3755-3763.
25. Thomas CF, Limper AH: **Pneumocystis pneumonia.** *New England Journal of Medicine* 2004, **350**(24):2487-2498.

26. Prasad B, Urbanski M, Ferguson TW, Karreman E, Tangri N: **Early mortality on continuous renal replacement therapy (CRRT): the prairie CRRT study.** *Canadian Journal of Kidney Health & Disease* 2016, **3**(1):36.
27. Llibre JM, Boris R, Samuel V, Lopez-Nuñez JJ, Arellano O, Marin JM, Santos JR, Paola M, Marta M, Paola Z: **Pneumocystis jirovecii pneumonia in HIV-1-infected patients in the late-HAART era in developed countries.** *Scandinavian Journal of Infectious Diseases* 2013, **45**(8):635-644.
28. J Scott B, Wald EL: **Long-duration (>4 weeks) continuous renal replacement therapy in critical illness.** *International Journal of Artificial Organs* 2010, **33**(10):716.
29. Cho AY, Yoon HJ, Lee KY, Sun IO: **Clinical characteristics of sepsis-induced acute kidney injury in patients undergoing continuous renal replacement therapy.** *Renal Failure* 2018, **40**(1):403-409.
30. Kalim S, Szczech LA, Wyatt CM: **Acute Kidney Injury in HIV-Infected Patients.** *Seminars in Nephrology* 2008, **28**(6):556-562.
31. Wyatt CM, Klotman PE: **HIV-associated nephropathy in the era of antiretroviral therapy.** *American Journal of Medicine* 2007, **120**(6):488-492.
32. Wyatt CM, Arons RR, Klotman PE, Klotman ME: **Acute renal failure in hospitalized patients with HIV: risk factors and impact on in-hospital mortality.** *Aids* 2006, **20**(4):561-565.
33. Choi AI, Li Y, Parikh C, Volberding PA, Shlipak MG: **Long-term clinical consequences of acute kidney injury in the HIV-infected.** *Kidney International* 2010, **78**(5):478-485.
34. Islam FM: **Relative risk of renal disease among people living with HIV: a systematic review and meta-analysis.** *Bmc Public Health* 2012, **12**(1):234.
35. Izzedine H, Baumelou A, Deray G: **Acute renal failure in HIV patients.** *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association* 2007, **22**(10):2757-2762.
36. Lin P, Jingyuan L, Yang L, Hui Z, Hebing G, Jingjing H, Ningning Y, Yufeng L, Haofeng X, Jian X: **Acute Kidney Injury in Chinese HIV-Infected Patients: A Retrospective Analysis from the Intensive Care Unit.** *AIDS Patient Care and STDs.*
37. Franceschini N, Napravnik S, Jr EJ, Szczech LA, Finn WF: **Incidence and etiology of acute renal failure among ambulatory HIV-infected patients.** *Kidney International* 2005, **67**(4):1526.
38. Vachiat AI, Musenge E, Wade S, Naicker S: **Renal failure in HIV-positive patients—a South African experience.** *Ckjd Clinical Kidney Journal* 2013, **6**(6):584-589.

Tables

Table 1. Demographic and Clinical Characteristics of 122 AKI Patients Admitted to the Intensive Care Unit ICU, intensive care unit; HIV, human immunodeficiency virus; HAART, Highly Active Anti-Retroviral Therapy; PCP, Pneumocystis carinii pneumonia; CRRT, continuous renal replacement therapy; SOFA, IQR, interquartile range; APACHE-II, acute physiology and chronic health evaluation, version II; SOFA, sequential organ failure assessment; GFR, Glomerular Filtration Rate; MPV, [Mean Platelet Volume](#).
p Value <0.05 was considered significant and is highlighted in bold

without CRRT n=90	p	Patients with AKI n=122	Patients with CRRT n=32	Patients	
Male(%)		112(91.8)	31(96.9)	81(90)	0.452
Age[years]		41[34-50]	42[37-55.5]	41[31-50]	0.137
Blood routine and biochemical items					
Lymphocyte count[×10 ⁹]		0.5[0.3-0.92]	0.54(0.34-1.10)	0.5(0.30-0.80)	0.205
Hemoglobin[g/L]		98.9±27.4	90.7±23.8	101.8±28.1	0.048
Albumin [g/L]		28.0±5.8	29.3±4.9	27.5±6.1	0.154
Total Bilirubin (u mol/L)		8.65[5.38-13.43]	7.75[5.03-15.33]	9.15[5.4-13.43]	0.682
Serum calcium[mmol/L]		1.92[1.77-2.09]	2.00[1.67-2.19]	1.92[1.82-2.05]	0.375
Items related to HIV infection					
CD4 counts at ICU admission		23(8-78)	37(13-122)	15(7-69)	0.043
Patients with HAART		30[24.6]	11[34.4]	19[21.1]	0.135
Items related to AKI					
The first Creatinine in Hospital (u mol/L)		72.7[54-129.3]	220.1[70.9-499.1]	64.5[51.8-92.6]	0.001
The highest Creatinine before in ICU(u mol/L)		48.9(34.7-70.8)	194.2(55.4-441.5)	42.1[32.8-58.6]	0.001
The highest Creatinine during ICU(u mol/L)		159.6(85.6-331)	375.4(293.3-580.0)	121.6(79.4-210.5)	0.001
Complication					
Sepsis (%)		104(85.2)	25(78.1)	79(87.8)	0.245
Septic Shock(%)		74(60.7)	19(59.4)	55(61.1)	0.863
PCP (%)		71(58.2)	12(37.5)	59(65.6)	0.006
Respiratory Failure (%)		81[66.4]	15(46.9)	65(72.2)	0.01
Multiple Organs Support Therapy					
The use of vasoactive agents (%)		81[66.4]	22[68.8]	59[65.6]	0.742
Duration of Mechanical ventilation (h)		131.5(16-264)	141.5(5-225.5)	124.5(24-264.0)	0.788
Severity of illness					
SOFA score at ICU admission		8[4-12]	12(6-16)	7(4-10)	0.001
APACHE-II score at ICU admission		20[15-28]	28(21-34)	18(15-23)	0.001
Outcome					
Death during in ICU		61(50)	18(56.3)	43(47.8)	0.41
Length of ICU stay (days), median (IQR)		9(5-16)	8(5-16)	9(5-17)	0.616
Length of hospital stay (days), median (IQR)		17(9-30)	15(7-21)	20(10-34)	0.022

Table 2. The comparison between Patients with CRRT and non-CRRT who were in AKI stage 3

	AKI stage 3 N=61	CRRT N=30	non-CRRT N=31	
p				
Male(%)	55(90.2)	29(96.7)	26(83.9)	0.195
Age[years]	44(37-50)	45(37-56)	44(36-48)	0.394
Blood routine and biochemical items				
Lymphocyte count($\times 10^9$)	0.5(0.25-1.00)	0.54(0.38-1.10)	0.5(0.2-0.8)	
	0.133			
Hemoglobin(g/L)	91(69.4-109)	91(69.3-108)		
	0.942			
Albumin(g/L)	27.1(23.6-31.6)	29.8(24.5-32.4)	26.8(22.3-30.2)	
	0.046			
T-Bil (umol/L)	8.6(5.4-16.2)	7.6(5-16.2)	11.4(6.3-16.0)	0.312
Serum calcium(mmol/L)	1.9(1.695-2.09)	1.95(1.67-2.17)	1.88(1.74-2.03)	
	0.341			
Lactate (mmol/L)	2.8(1.50-6.10)	4.05(1.6-7.3)		2.1
	0.056			
Serum phosphate(mmol/L)	1.11(0.81-1.67)	1.53(0.81-1.92)	1.02(0.81-1.36)	
	0.083			
LDH (U/L)	438(309.2-806.5)	451(254-1299)	450(321.2-663.2)	
	0.441			
Items related to HIV infection				
CD4 counts at ICU admission(cells/ml)	24(9-82)	37(13-127)	11(5-36)	
	0.007			
HIV viral load (copies/mL)	1600(64-245223)	1021(0-171876)	37444(1142-335614)	
	0.077			
HAART(%)	25(41)	9(30)	16(51.6)	0.054
Complication				
PCP (%)	29(47.5)	11(36.7)	18(58.1)	0.094
Septic Shock(%)	39(63.9)	17(56.7)	22(71)	0.245
Multiple Organs Support Therapy				
The use of vasoactive agents(%)	44(72.1)	20(66.7)	24(77.4)	
	0.349			
Duration of Mechanical ventilation (h)	129(4-240)	152(0-271)	119(14-212.5)	
	0.822			
Severity of illness				
SOFA score at ICU admission (scores)	9(6-13)	11(7-14)	9(6-11)	
	0.13			
APACHE-II score at ICU admission(scores)	23(19-33)	28(21-37)	19(18-30)	
	0.019			
Outcome				
Death during in ICU	32(52.5)	14(46.7)	18(58.1)	0.373
Renal recovery	17(27.9)	7(23.3)	10(32.3)	0.437
Length of ICU stay (days), median (IQR)	8(5-14)	9(6-16)	6(5-14)	
	0.529			
Length of hospital (days), median (IQR)	16(9-30)	15(7-22)	17(12-38)	0.034

T-Bil, total bilirubin; HAART, Highly Active Anti-Retroviral Therapy; PCP, Pneumocystis carinii pneumonia; CRRT, continuous renal replacement therapy; ICU, intensive care unit; IQR, interquartile range; APACHE-II, acute physiology and chronic health evaluation, version II; SOFA, sequential organ failure assessment.

p Value <0.05 was considered significant and is highlighted in bold

Table 3. Univariate Analysis for the Identification of Predictors the Death of CRRT in ICU

	Odds ratio	95% Confidence interval	p
Respiratory Failure	7.333	1.467-36.664	0.015
Septic Shock	1.005	1.001-1.010	0.018
The use of vasoactive agents	10.667	1.743-65.271	0.001
Duration of Mechanical Ventilation	1.011	1.002-1.019	0.011
PCP	7.50	1.288-43.687	0.025
SOFA score at ICU admission	1.183	1.012-1.383	0.035
Duration of CRRT	1.014	1.001-1.028	0.034

CRRT, continuous renal replacement therapy; ICU, intensive care medicine; SOFA, sequential organ failure assessment; PCP, Pneumocystis carinii pneumonia.

p Value <0.05 was considered significant and is highlighted in bold.

Table 4. Logistics Multivariate Analysis for the Identification of Predictors the Death of CRRT in ICU

	Odds ratio	95% Confidence interval	p
Septic shock	151.256	2.842-8051.975	0.013
PCP	52.698	1.092-2543.904	0.045
Duration of CRRT	1.045	1.007-1.085	0.020

CRRT, continuous renal replacement therapy; ICU, intensive care medicine; PCP, Pneumocystis carinii pneumonia.

p Value <0.05 was considered significant and is highlighted in bold.

Table 5. The Cox Analysis for the cumulative survival of AKI 3 patients between the CRRT and non-CRRT

	groups		
	Odds ratio	95% Confidence interval	
p			
CRRT	1.372	0.746-2.521	0.309
The possibility of using vasoactive agents	2.501	1.205-5.192	0.014
Duration of Mechanical Ventilation	0.998	0.997-0.999	0.006
APACHE II score	1.023	0.990-1.057	0.176

CRRT, continuous renal replacement therapy; ICU, intensive care unit; APACHE-II, acute physiology and chronic health evaluation, version II;
p Value <0.05 was considered significant and is highlighted in bold.

Figures

Figure 1

Study flow chart detailing the inclusion and exclusion of patients (June 3, 2005, to May 21, 2017). AKI, acute kidney injury; ICU, intensive care unit; CRRT, continuous renal replacement therapy; n, number. 59 patients were excluded: 47 patients were excluded as the length of stay in ICU $\geq$ 48 hours; 8 were admitted more than once within 6 months; 4 underwent RRT before admission

Figure 2

Cause for admission ICU and death number of the 32 CRRT patients. ICU, intensive care medicine; CRRT, continuous renal replacement therapy.

Figure 3

Cumulative survival curves of HIV infected patients who were diagnosed with AKI 3 admitted to the intensive care unit, received CRRT or not received (two groups). HIV, human immunodeficiency virus; CRRT, continuous renal replacement therapy. It shows no significant differences of survival between the group of CRRT and non-CRRT ($p = 0.309$).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [supplementarymaterial.pdf](#)